Berberine can reduce urinary microalbumin, the body mass index, and postprandial blood glucose and triglyceride levels in MetS patients by regulating glucose and lipid metabolism, endoplasmic reticulum stress, inflammatory factors, insulin resistance, oxidative stress, and intestinal microbiota (145–148). The gene discussed is INS; the disease is metabolic syndrome.